

1 SARS-CoV-2 RNA viremia is associated with a sepsis-like host response and critical 2 illness in COVID-19

3 Jesús F Bermejo-Martin^{1,2,3*}, Milagros González-Rivera^{4,5*}, Raquel Almansa^{1,2,3*}, Dariela
4 Micheloud^{6*}, Marta Domínguez-Gil^{7*}, Salvador Resino^{8*}, Marta Martín-Fernández^{1,2},
5 Pablo Ryan Murua⁹, Felipe Pérez-García¹⁰, Luis Tamayo^{1,11}, Raúl Lopez-Izquierdo¹²,
6 Elena Bustamante¹³, César Aldecoa^{1,14,15}, José Manuel Gómez¹⁶, Jesús Rico-Feijoo^{1,15},
7 Antonio Orduña¹⁷, Raúl Méndez¹⁸, Isabel Fernández Natal¹⁹, Gregoria Megías²⁰,
8 Montserrat González-Estecha^{4,5}, Demetrio Carriedo²¹, Cristina Doncel^{1,2,3}, Noelia Jorge
9^{1,2,3}, Félix del Campo²², José Antonio Fernández-Ratero²³, Wysali Trapiello²⁴, Paula
10 González-Jiménez¹⁸, Guadalupe Ruiz²⁴, Alyson A. Kelvin^{25,26}, Ali Toloue
11 Ostadgavahi^{25,26}, Ruth Oneizat⁷, Luz María Ruiz⁷, Iria Miguéns⁶, Esther Gargallo⁶, Ioana
12 Muñoz⁶, Sara Pelegrin¹⁵, Silvia Martín^{1,15}, Pablo García Olivares¹⁶, Jamil Antonio
13 Cedeño¹⁶, Tomás Ruiz Albi²², Carolina Puertas⁴, Jose Ángel Berezo^{1,11}, Gloria Renedo¹³,
14 Rubén Herrán^{1,11}, Juan Bustamante-Munguira²⁷, Pedro Enríquez¹¹, Ramón Cicuendez¹³,
15 Jesús Blanco¹¹, Jesica Abadia²⁸, Julia Gómez Barquero²⁸, Nuria Mamolar¹³, Natalia
16 Blanca-López⁹, Luis Jorge Valdivia²¹, Belén Fernández Caso¹⁹, María Ángeles
17 Mantecón²⁰, Anna Motos^{3,29}, Laia Fernandez-Barat^{3,29}, Ricard Ferrer^{3,30}, Ferrán Barbé^{3,31},
18 Antoni Torres^{3,29}^Δ, Rosario Menéndez^{3,18}^Δ, José María Eiros⁷^Δ, David J Kelvin^Δ^{25,26}.

19 * These authors contributed equally

20 ^Δ These authors contributed equally

21

22 1. Group for Biomedical Research in Sepsis (BioSepsis). Instituto de Investigación

23 Biomédica de Salamanca, (IBSAL), Paseo de San Vicente, 58-182, 37007 Salamanca,

24 Spain

- 25 2. Hospital Universitario Río Hortega, Calle Dulzaina, 2, 47012 Valladolid, Spain.
- 26 3. Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES),
27 Instituto de Salud Carlos III, Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain
- 28 4. Department of Laboratory Medicine, Hospital General Universitario Gregorio Marañón,
29 Calle del Dr. Esquerdo, 46, 28007 Madrid, Spain.
- 30 5. Department of Medicine, Faculty of Medicine, Universidad Complutense de Madrid,
31 Plaza de Ramón y Cajal, s/n, 28040 Madrid, Spain.
- 32 6. Emergency Department, Hospital General Universitario Gregorio Marañón, Calle del
33 Dr. Esquerdo, 46, 28007 Madrid, Spain.
- 34 7. Microbiology Service, Hospital Universitario Río Hortega, Calle Dulzaina, 2, 47012
35 Valladolid, Spain
- 36 8. Viral Infection and Immunity Unit, Centro Nacional de Microbiología, Instituto de
37 Salud Carlos III, Ctra. de Pozuelo, 28, 28222 Majadahonda, Spain
- 38 9. Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain
- 39 10. Servicio de Microbiología Clínica, Hospital Universitario Príncipe de Asturias, Carr.
40 de Alcalá, s/n, 28805, Madrid, Spain
- 41 11. Intensive Care Unit, Hospital Universitario Río Hortega, Calle Dulzaina, 2, 47012
42 Valladolid, Spain.
- 43 12. Emergency Department, Hospital Universitario Río Hortega, Calle Dulzaina, 2, 47012
44 Valladolid, Spain.
- 45 13. Intensive Care Unit, Hospital Clínico Universitario de Valladolid. Av. Ramón y Cajal,
46 3, 47003 Valladolid, Spain

47 14. Department of Anesthesiology, Facultad de Medicina de Valladolid, Av. Ramón y
48 Cajal, 7, 47005 Valladolid, Spain.

49 15. Anesthesiology and Reanimation Service, Hospital Universitario Río Hortega, Calle
50 Dulzaina, 2, 47012 Valladolid, Spain.

51 16. Intensive Care Unit. Hospital General Universitario Gregorio Marañón. Calle del Dr.
52 Esquerdo, 46, 28007 Madrid, Spain.

53 17. Microbiology Service, Hospital Clínico Universitario de Valladolid, Av. Ramón y
54 Cajal, 3, 47003 Valladolid, Spain.

55 18. Pulmonology Service, Hospital Universitario y Politécnico de La Fe, Avinguda de
56 Fernando Abril Martorell, 106, 46026, Valencia Spain

57 19. Clinical Microbiology Department. Complejo Asistencial Universitario de León. Calle
58 Altos de nava, s/n, 24001 León, Spain.

59 20. Microbiology Service, Hospital Universitario de Burgos, Av. Islas Baleares, 3, 09006
60 Burgos, Spain

61 21. Intensive Care Unit. Complejo Asistencial Universitario de León. Calle Altos de nava,
62 s/n, 24001 León, Spain.

63 22. Pneumology Service, Hospital Universitario Río Hortega / Biomedical Engineering
64 Group, Universidad de Valladolid, Calle Dulzaina, 2, 47012 Valladolid, Spain.

65 23. Intensive Care Unit. Hospital Universitario de Burgos, Av. Islas Baleares, 3, 09006
66 Burgos, Spain.

67 24. Clinical Analysis Service. Hospital Clínico Universitario de Valladolid, Av. Ramón y
68 Cajal, 3, 47003 Valladolid, Spain

69 25. Department of Microbiology and Immunology, Faculty of Medicine, Dalhousie
70 University, Halifax, Nova Scotia, B3H 4R2, Canada

71 26. International Institute of Infection and Immunity, Shantou University Medical College,
72 22 Xinling Rd, Jinping, Shantou, Guangdong, China.

73 27. Department of Cardiovascular Surgery, Hospital Clínico Universitario de Valladolid.
74 Av. Ramón y Cajal, 3, 47003 Valladolid, Spain

75 28. Infectious diseases clinic, Internal Medicine Department, Hospital Universitario Río
76 Horteiga, Valladolid, Calle Dulzaina, 2, 47012 Valladolid, Spain

77 29. Department of Pulmonology, Hospital Clinic de Barcelona, Universidad de Barcelona,
78 Institut D investigacions August Pi I Sunyer (IDIBAPS), Carrer del Rosselló, 149, 08036
79 Barcelona, Spain.

80 30. Intensive Care Department, Vall d'Hebron Hospital Universitari. SODIR Research
81 Group, Vall d'Hebron Institut de Recerca, Passeig de la Vall d'Hebron, 119, 08035
82 Barcelona, Spain.

83 31. Respiratory Department, Institut Ricerca Biomedica de Lleida, Av. Alcalde Rovira
84 Roure, 80, 25198 Lleida, Spain.

85 **Corresponding author:** David J Kelvin Department of Microbiology and Immunology,
86 Dalhousie University, Halifax, Nova Scotia, B3H 4R2, Canada. E-mail address:
87 dkelvin@jcdc.org.

88

89

90

91 **Abstract**

92 **Background:** Severe COVID-19 is characterized by clinical and biological manifestations
93 typically observed in sepsis. SARS-CoV-2 RNA is commonly detected in nasopharyngeal
94 swabs, however viral RNA can be found also in peripheral blood and other tissues.
95 Whether systemic spreading of the virus or viral components plays a role in the
96 pathogenesis of the sepsis-like disease observed in severe COVID-19 is currently
97 unknown.

98 **Methods:** We determined the association of plasma SARS-CoV-2 RNA with the
99 biological responses and the clinical severity of patients with COVID-19. 250 patients with
100 confirmed COVID-19 infection were recruited (50 outpatients, 100 hospitalised ward
101 patients, and 100 critically ill). The association between plasma SARS-CoV-2 RNA and
102 laboratory parameters was evaluated using multivariate GLM with a gamma distribution.
103 The association between plasma SARS-CoV-2 RNA and severity was evaluated using
104 multivariate ordinal logistic regression analysis and Generalized Linear Model (GLM)
105 analysis with a binomial distribution.

106 **Results:** The presence of SARS-CoV-2-RNA viremia was independently associated with a
107 number of features consistently identified in sepsis: 1) high levels of cytokines (including
108 CXCL10, CCL-2, IL-10, IL-1ra, IL-15, and G-CSF); 2) higher levels of ferritin and LDH;
109 3) low lymphocyte and monocyte counts 4) and low platelet counts. In hospitalised
110 patients, the presence of SARS-CoV-2-RNA viremia was independently associated with
111 critical illness: (adjusted OR= 8.30 [CI95%=4.21 - 16.34], $p < 0.001$). CXCL10 was the
112 most accurate identifier of SARS-CoV-2-RNA viremia in plasma (area under the curve
113 (AUC), [CI95%], p) = 0.85 [0.80 – 0.89], <0.001), suggesting its potential role as a
114 surrogate biomarker of viremia. The cytokine IL-15 most accurately differentiated clinical
115 ward patients from ICU patients (AUC: 0.82 [0.76 – 0.88], <0.001).

116 **Conclusions:** systemic dissemination of genomic material of SARS-CoV-2 is associated
117 with a sepsis-like biological response and critical illness in patients with COVID-19. RNA
118 viremia could represent an important link between SARS-CoV-2 infection, host response
119 dysfunction and the transition from moderate illness to severe, sepsis-like COVID-19
120 disease.

121

122 **Key words:** SARS-CoV-2, cytokine, sepsis, COVID-19, plasma, viremia, ICU

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141 **Background**

142 With well over 26 million cases and 863,516 deaths globally, Coronavirus disease 2019
143 (COVID-19) has become the top economic and health priority worldwide [1]. Among
144 hospitalized patients, around 10–20% are admitted to the intensive care unit (ICU), 3–10%
145 require intubation and 2–5% die [2]. Severe COVID-19 is characterized by clinical and
146 biological manifestations typically observed in sepsis or septic shock, including cold
147 extremities and weak peripheral pulse, even in the absence of overt hypotension [3].
148 Patients with severe COVID-19 show marked signs of dysregulated host response(s) to
149 infection, which are also observed in sepsis: this includes elevation of acute phase reactants
150 and cytokines, transaminases, and ferritin, the activation of the coagulation pathways, the
151 presence of lymphopenia and low platelet counts, the elevation of biomarkers of
152 endothelial dysfunction, and the emergence of signs of profound immunological alteration
153 [4] [5] [6]. It is not surprising that severe COVID-19 has been proposed as a “viral
154 sepsis” [3] [7].

155 SARS-CoV-2 RNA is commonly detected in nasopharyngeal swabs; however viral RNA
156 can be found in sputum, lung samples, peripheral blood, serum, stool samples, and to a
157 limited extent urine [8] [9] [10] [11]. While the lungs are most often affected, severe
158 COVID-19 can also induce inflammatory cell infiltration, haemorrhage, and degeneration
159 or necrosis in extra-pulmonary organs (spleen, lymph nodes, kidney, liver, central nervous
160 system) [3]. Whether systemic distribution of the virus or viral components plays a role in
161 the pathogenesis of the “sepsis-like” clinical presentation [3] or in the dysregulated
162 response to the infection observed in severe COVID-19 is currently unknown.

163 In this study, by using an integrative approach, we evaluated the impact of SARS-CoV-2
164 RNA viremia on a number of biological parameters altered both in COVID-19 and sepsis.

165 We also studied the association between the presence of SARS-CoV-2 RNA in peripheral
166 blood plasma and disease severity.

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183 **Methods**

184 **Study design:** 250 adult patients with a positive nasopharyngeal swab polymerase chain
185 reaction (PCR) test for SARS-CoV-2 administered at participating hospitals were recruited
186 during the first pandemic wave in Spain from March 16th to the 15th of April 2020. The
187 patients recruited were of three different categories. The first corresponded to patients
188 examined at an emergency room and discharged within the first 24 hours (outpatients
189 group, n=50). The second group were patients hospitalized to pneumology, infectious
190 diseases or internal medicine wards (wards group, n=100). Patients who required critical
191 care or died during hospitalization were excluded from this group, in order to have a group
192 of clear moderate severity. The third group corresponded to patients admitted to the ICU
193 (n=100). Patient`s recruited by participating hospital are detailed in the additional file 1.
194 This is a preliminary report on the biomarkers` sub-study of the CIBERES-UCI-COVID
195 study registered at Clinicaltrials.gov with the identification NCT04457505.

196 **Blood samples:** Plasma from blood collected in EDTA tubes samples was obtained from
197 the three groups of patients in the first 24 hours following admission to the emergency
198 room, to the ward, or to the ICU, at a median collection day since disease onset of 7, 8 and
199 10 respectively, and also, from 20 blood donors (10 men and 10 women).

200 **Laboratory works:** immunological mediators were profiled in plasma using the Ella-
201 SimplePlex™ (San Jose, California, U.S.A) immunoassay. RNA was extracted from 150
202 µl of plasma using an automated system, eMAG® from bioMérieux® (Marcy l'Etoile,
203 France). Detection of SARS-CoV-2 RNA was performed in five µl of the eluted solution
204 using the CLART® COVID-19 platform from Genomica® (Madrid, Spain). IgG specific
205 for the Nucleocapsid Protein of SARS-CoV-2 was detected in 150 µl of plasma using the
206 Abbott Architect SARS-CoV-2 IgG Assay (Illinois, U.S.A).

207 **Statistical analysis:** Statistical analysis was performed by using Statistical Package for the
208 Social Science (SPSS) 20.0 (SPSS INC, Chicago, IL, U.S.A), Stata 15.0 (StataCorp, Texas,
209 U.S.A) and Minitab 19.2 software. For the demographic and clinical characteristics of the
210 patients, the differences between groups were assessed using the Chi-square test for
211 categorical variables. Differences for continuous variables were assessed by using the
212 Kruskal-Wallis test with post hoc tests adjusting for multiple comparisons. Statistical
213 association analysis was performed using different regression models to assess the
214 relationship between viremia and outcome variables. An ordinal logistic regression (OLR)
215 model was used considering the outcome variable as ordinal (outpatients, wards, and ICU),
216 providing an odds ratio (OR). Generalized Linear Models (GLM) with binomial
217 distribution were used when the outcome variable was dichotomous (outpatients vs. wards,
218 and wards vs. ICU), also providing an odds ratio (OR). GLM with a gamma distribution
219 (log-link) was used when the outcome variable was continuous, providing arithmetic mean
220 ratios (AMR). In all cases, the analysis was performed first without adjustment and was
221 later adjusted for the most relevant covariates in our study. P-values were corrected using
222 the false discovery rate (FDR) with the Benjamini and Hochberg (q-values) procedure.

223

224

225

226

227

228

229

230 **Results**

231 **Clinical characteristics of the patients** (Table 1): Patients diagnosed with SARS-CoV-2
232 infection based on a positive nasopharyngeal test and requiring hospitalization (either
233 general ward or ICU) were older (median 64 years of age for ward and 66 years for ICU)
234 than those patients discharged to their home from the ER (median age 48 years of age).
235 There were no significant differences regarding age between ward and ICU hospitalised
236 patients. Critically ill patients (ICU admitted) were more frequently male than those in the
237 other groups. Comorbidities of obesity, hypertension, dyslipidemia and type II diabetes
238 were more commonly found in patients requiring hospitalization, with no significant
239 differences found in the comorbidities profile between critically ill and non-critically ill
240 hospitalized patients. ICU patients showed significantly lower levels of O₂ saturation at the
241 time of admission to the ICU compared to other patients admitted to the ER or the ward.
242 100% of ICU patients presented with pulmonary infiltrates of whom 93 % also had
243 bilateral pneumonia, these findings were significantly higher than the incidence of
244 pulmonary infiltrates and bilateral pneumonia found in the other two groups. Glucose
245 levels were higher in the group of critically ill patients, who also showed higher values of
246 INR, D-dimers, LDH, GPT, ferritin, C-reactive protein and lower haematocrit. ICU
247 patients showed pronounced lymphopenia and lower monocyte counts; however,
248 neutrophil counts were increased. ICU patients more frequently received experimental
249 treatments during their hospitalization period, including hydroxicloroquine, corticoids,
250 remdesivir, tocilizumab, lopinavir/ritonavir or beta-interferon. ICU patients stayed longer
251 in the hospital, with 48 % fatalities reported in this group. The number of missing values
252 for the variables registered in this study are reported in the additional file 2.

253

254

255 Impact of SARS-CoV-2-RNA viremia on laboratory parameters:

256 Multivariate GLM analysis showed that SARS-CoV-2-RNA viremia was an independent
257 marker of high levels of ferritin, LDH and high levels of chemokines (CXCL10, CCL-2),
258 cytokines (IL-15, IL-10, IL-1ra) and GCS-F (Figure 1 and additional file 3). In contrast,
259 viremia was independently associated to low lymphocyte, monocyte and platelet counts
260 and low levels of IL-4 in plasma (Figure 1 and additional file 3). Patients requiring
261 hospitalization in the ward showed significantly increased levels of IL-10, CXCL0, IL-1ra,
262 IL-6 and TNF- α compared to outpatients. Critically ill patients showed significantly higher
263 levels of GM-CSF, CXCL10, CCL2, IL-10, IL-6 and IL-15 compared to ward patients and
264 outpatients (figure 2 and additional file 4).

265 **Prevalence of SARS-CoV-2-RNA viremia and specific SARS-Cov-2 IgG.** To assess the
266 possible systemic nature of SAS-CoV-2 infections in hospitalized patients we determined
267 the presence of SARS-CoV-2 RNA in plasma. As depicted in table 1 and figure 3, the
268 frequency of SARS-CoV-2-RNA viremia was higher the critically ill patients (82%)
269 compared to ward patients (36%) and outpatients (22%) ($p < 0.001$). No statistical
270 differences were found in plasma viral RNA between the outpatients and the patients in the
271 ward ($p = 0.081$). Critically ill patients also had a higher frequency of specific SARS-CoV-
272 2 IgG responses than the other groups (70% in ICU compared to 52% and 49% in the
273 outpatients and ward groups, $p < 0.05$, table 1 and figure 3). No significant differences
274 were found between the group of outpatients and those admitted to the ward.

275 **SARS-CoV-2-RNA viremia and disease severity.** When the association between viremia
276 and clinical status was evaluated, multivariate ordinal logistic regression analysis revealed
277 that SARS-CoV-2-RNA viremia was a predictor of severity across the three categories
278 considered in our study [OR= 8.24, $p < 0.001$, (CI 95%= 4.71; 14.41)] (see additional file
279 5). When we compared outpatients with admitted ward patients, multivariate GLM

280 analysis showed that viremia was not significantly associated with either group (Table 2).

281 In contrast, when the group of ward patients was compared to ICU patients, multivariate

282 GLM analysis showed that viremia was strongly associated with patient severity requiring

283 critical care [OR = 8.3, $p < 0.001$, (CI 95% = 4.21-16.34)] (Table 2). In the patients

284 admitted to the ICU, no significant difference in the prevalence of SARS-CoV-2-RNA was

285 found between survivors and non survivors: 42 out of 48 of non survivors had viremia

286 (87.5%), while 40 out of 52 survivors (76.9%) had viremia, $p = 0.169$.

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301 **Discussion**

302 Our study demonstrates that the presence of SARS-CoV-2 RNA in the plasma of patients
303 with COVID-19 is associated to a number of biological alterations typically found in
304 sepsis. Viremia was an independent predictor of high levels of chemokines (CXCL10,
305 CCL2) and cytokines (IL-10, IL-1ra, IL-15, G-CSF). These chemokines and cytokines
306 have also been reported to be elevated in sepsis [12] [13] [14] [15]. Recognition of viral
307 RNA by endosomal receptors such as toll like receptor 7 (TLR7) in human plasmacytoid
308 dendritic cells and B cells, or TLR8 in myeloid cells, activate intracellular signalling
309 pathways enhancing cytokine production [16]. In fact, it has recently been demonstrated
310 that SARS-CoV-2 genome has more single-stranded RNA fragments that could be
311 recognized by TLR7/8 than the SARS-CoV-1 genome, which suggests the potential of
312 SARS-CoV-2 to induce hyperactivation of innate immunity [17]. In our study, CXCL10
313 was the most accurate identifier of viremia in plasma (area under the curve (AUC),
314 [CI95%], p) = 0.85 [0.80 – 0.89], <0.001), supporting its potential role as a surrogate
315 biomarker of SARS-CoV RNA viremia. Signalling via the CXCL10 cognate receptor,
316 CXCR3, mediates immunopathology during other highly pathogenic respiratory virus
317 infections such as H5N1 influenza virus [18]. CCL2 is one of the key chemokines that
318 regulate migration and infiltration of monocytes/macrophages [19]. We had already
319 demonstrated that SARS patients had increased levels of CXCL10 and CCL2 in serum
320 during the early onset of symptoms [20]. IL-10 and IL-1ra are major immunomodulatory
321 cytokines inducing immunosuppression. Zhao Y et al reported IL-10 and IL-1ra to be
322 associated with the severity of COVID-19 [21]. Whether elevation of IL-10 and IL-1RA
323 represents a mechanism of viral evasion or an attempt of the immune system to control an
324 exuberant inflammatory response remains to be elucidated [22] [23]. The association
325 between SARS-CoV-2-RNA viremia and IL-15 is also especially intriguing, since IL-15

326 was the cytokine which most accurately differentiated clinical ward patients from ICU
327 patients (AUC: 0.82 [0.76 – 0.88], <0.001). Previously, we identified IL-15 as a signature
328 of critical illness in the H1N1 2009 influenza pandemics [24]. IL-15 is a pleiotropic
329 cytokine that induces T-cell proliferation and enhances natural killer (NK) cell cytotoxicity
330 [25]. It may also play an essential role in T cell or NK cell mediated tissue destruction
331 [26]. During Hantavirus infection, IL-15 drives a massive NK cell response with high
332 levels of IL-15 associated with severe disease and fatal outcome [27]. Recently, it was
333 reported that circulating NK cells were elevated in COVID-19 severe patients [28]
334 illustrating the potentially important role of IL-15 in regulating NK function during
335 COVID-19 pathogenesis. The role of G-CSF in COVID-19 is currently under discussion.
336 In patients with cancer and COVID-19, administration of G-CSF was associated with an
337 increased need for high oxygen supplementation and death [29]. It has been proposed that
338 G-CSF could worsen lung function by causing neutrophil infiltration [30]. During the 2009
339 influenza pandemics, we demonstrated that, in critically patients, high levels of G-CSF in
340 plasma translated into diminished survival [31].

341 Viremia was also associated with higher levels of ferritin in COVID-19 patients in our
342 study. Ferritin is an acute-phase reactant, commonly triggered by inflammation and
343 infection. Sepsis patients frequently present with elevated serum ferritin, where it is related
344 to poor clinical outcome [32]. In a recent metanalysis, Khinda et al evidenced also the
345 association between ferritin and mortality in COVID-19 [33]. Viremia also correlated with
346 higher levels of LDH, a marker of necrosis and cellular injury. High levels of LDH are
347 increased in non survivors in sepsis [34] and also in COVID-19 [33]. The association of
348 viremia with high LDH levels and lower O₂ saturation supports viral involvement in the
349 genesis of tissue damage and respiratory failure in patients with severe COVID-19.

350 Another shared hallmark of sepsis and COVID-19 is the presence of lymphopenia and
351 monocytopenia [35] [36] [37] [4]. In COVID-19 patients, our study demonstrates that the
352 presence of viremia was associated with lower lymphocyte and monocyte counts in
353 peripheral blood. In sepsis, the presence of low platelet counts is assessed in the Sequential
354 Organ failure score (SOFA) as a parameter indicating coagulation failure [38]. In our
355 study, the presence of viremia in COVID-19 patients was associated to lower platelet
356 counts. Even though platelet counts did not show significant variation across the three
357 severity groups (Table 1), those patients with SARS-CoV-2-RNA viremia showed
358 significantly lower platelet counts than the other patients (198,000 vs 230,000 cells/mm³, p
359 = 0.003). In turn, critically ill non survivors showed lower platelet counts than survivors
360 (179,000 vs 221,000 cells/mm³, p = 0.001).

361 Our work identifies a connection between viremia and severe clinical presentation of
362 COVID-19. SARS-CoV-2 viral RNA is detected in the plasma of the vast majority of those
363 COVID-19 patients admitted to the ICU (82%). In hospitalized COVID-19 patients, the
364 presence of SARS-CoV-2-RNA viremia translates into an 8-fold increase in the risk of
365 presenting critical illness, independently of age, sex and major comorbidities. In turn,
366 critically ill COVID-19 patients were those showing the greatest alterations in cytokine,
367 ferritin, LDH, lymphocyte and monocyte levels. These findings identify viremia as an
368 important link between SARS-CoV-2 infection and the development of sepsis-like disease
369 in COVID-19 patients, suggesting that the presence of viraemic SARS-CoV-2 RNA in the
370 plasma could be playing a major role in the transition of moderate illness to severe
371 COVID-19. The underlying mechanisms or processes leading to the viraemic state are not
372 understood at this time, however, lymphopenia, hypercytokinemia, and increased
373 expression of IL-10 and IL-1RA may represent dysfunctional host responses to the virus
374 allowing for dissemination of viral components and perhaps the virus itself. The possibility

375 of systemic viral infections in multiple organs remains to be elucidated. From a clinical
376 management point of view recognizing severe COVID-19 as a sepsis-like disease suggests
377 that targeting the virus as an infectious agent causing sepsis would require early
378 intervention with antiviral strategies (drugs or convalescent / hyperimmune sera,
379 monoclonal antibodies), similar to treatment of bacterial sepsis with antibiotics.
380 Furthermore, using CXCL-10 and IL-15 as surrogate markers for viremia and critical
381 illness could facilitate indirect identification of the “septic-like” state, as proteins are easier
382 to profile than viremic RNA.

383 Finally, most ICU patients with SARS-CoV-2-RNA viremia had already developed a
384 specific IgG response against the virus (70.7 %), which would support the notion that
385 continued viral replication is a persistent event during antibody responses.

386 As a limitation of our study is we did not determine if the findings of viral RNA in plasma
387 reflects the presence of live virus in peripheral blood. However, the SARS-CoV-2 virus
388 has been reported to be difficult to culture from blood. [9] Another limitation of our study
389 is that we did not evaluate viral load. Our group is currently working in determining viral
390 load quantification and viral growth from plasma.

391 **Conclusions**

392 Systemic dissemination of SARS-CoV-2 genomic material in patients with COVID-19 is
393 strongly associated with biological responses typically observed in sepsis. RNA-viremia is
394 a marker of critical illness in COVID-19 patients. Prompt identification of viremia could
395 help to early detect those patients at risk of clinical deterioration. Early control of viremia
396 could contribute to improve survival.

397

398

399 **List of abbreviations**

400 SARS-CoV-2: Severe acute Respiratory Syndrom-Coronavirus-2

401 LDH: Lactate dehydrogenase

402 G-CSF: Granulocyte colony-stimulating factor

403 TLR: toll like receptor

404

405 **Declarations**

406 **Ethics approval and consent to participate:** The study was approved by the Committee

407 for Ethical Research of the coordinating institution, “Comite de Etica de la Investigacion

408 con Medicamentos del Area de Salud de Salamanca”, code PI 2020 03 452. Informed

409 consent was obtained orally when clinically possible. In the remaining cases, the informed

410 consent waiver was authorized by the Ethics committee.

411 **Consent for publication:** not applicable

412 **Availability of data and materials:** the datasets generated and/or analysed during the

413 current study are not publicly available since they are still under elaboration for publication

414 by the authors but are available from the corresponding author on reasonable request.

415 **Competing interests**

416 The authors declare that they have no competing interests

417 **Funding**

418 This work was supported by awards from the Canadian Institutes of Health Research, the

419 Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding initiative (CIHR

420 OV2 – 170357), Research Nova Scotia (DJK), Atlantic Genome/Genome Canada (DJK),

421 Li-Ka Shing Foundation (DJK), Dalhousie Medical Research Foundation (DJK), the
422 “Subvenciones de concesión directa para proyectos y programas de investigación del virus
423 SARS-CoV2, causante del COVID-19”, FONDO - COVID19, Instituto de Salud Carlos
424 III (COV20/00110, CIBERES, 06/06/0028), (AT) and finally by the “Convocatoria
425 extraordinaria y urgente de la Gerencia Regional de Salud de Castilla y León, para la
426 financiación de proyectos de investigación en enfermedad COVID-19” (GRS COVID
427 53/A/20) (CA). DJK is a recipient of the Canada Research Chair in Translational
428 Vaccinology and Inflammation. The funding sources did not play any role neither in the
429 design of the study and collection, not in the analysis, in the interpretation of data or in
430 writing the manuscript.

431 **Authors ‘contribution:** JFBM, DJK, JB, RF, FB, AT and RM designed the study. JFBM
432 and DJK wrote the manuscript and interpreted the data. RA coordinated the clinical study
433 and drafted the figures. MGR, DM, PR, FPG, LT, RLI, EB, CA, JMG, JR, RM, MIF, GM,
434 MGE, DC, FDC, JFR, WT, PGJ, GR, IM, EG,IM, SP, SM, PGO, JAC, TRA, CP, JAB,
435 GR, RH, JB, PE, RC, JA, JGB, NM, NBL, LJV, BFC, MAM recruited the patients and /or
436 collected the clinical data. MDG, AO, RO, LMR and JME performed the assays for the
437 detection of SARS-CoV-2 IgG and viremia. CD and NJ profiled the immunological
438 mediators. SR and MMF developed the statistical analysis and drafted the figures. AAK,
439 ATO, AM and LF performed the literature search. All authors read and approved the final
440 manuscript.

441

442 **Acknowledgements:** we thank SEIMC-GESIDA Foundation for the scientific sponsoring of
443 this project. We thank also the “Centro de Hemoterapia y Hemodonación de Castilla y
444 León, CHEMCYL”, which provided the plasma samples used in the healthy control group.

445 **References:**

- 446 1. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at
447 Johns Hopkins University (JHU) [Internet]. Available from:
448 <https://coronavirus.jhu.edu/map.html>
- 449 2. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics
450 of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;
- 451 3. Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis:
452 observations and hypotheses. *Lancet*. 2020;395:1517–20.
- 453 4. Bao J, Li C, Zhang K, Kang H, Chen W, Gu B. Comparative analysis of laboratory
454 indexes of severe and non-severe patients infected with COVID-19. *Clin Chim Acta*.
455 2020;509:180–94.
- 456 5. Hupf J, Muströph J, Hanses F, Evert K, Maier LS, Jungbauer CG. RNA-expression of
457 adrenomedullin is increased in patients with severe COVID-19. *Crit Care*. 2020;24:527.
- 458 6. Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, et al. COVID-19:
459 immunopathogenesis and Immunotherapeutics. *Signal Transduct Target Ther*.
460 2020;5:128.
- 461 7. López-Collazo E, Avendaño-Ortiz J, Martín-Quirós A, Aguirre LA. Immune
462 Response and COVID-19: A mirror image of Sepsis. *Int J Biol Sci*. 2020;16:2479–89.
- 463 8. Cevik M, Bamford CGG, Ho A. COVID-19 pandemic—a focused review for
464 clinicians. *Clinical Microbiology and Infection*. Elsevier; 2020;26:842–7.
- 465 9. Zhang W, Du R-H, Li B, Zheng X-S, Yang X-L, Hu B, et al. Molecular and
466 serological investigation of 2019-nCoV infected patients: implication of multiple
467 shedding routes. *Emerging Microbes & Infections*. Taylor & Francis; 2020;9:386–9.
- 468 10. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable Serum Severe
469 Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely
470 Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With
471 Coronavirus Disease 2019. *Clin Infect Dis* [Internet]. [cited 2020 Jul 6]; Available
472 from: <https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa449/5821311>
- 473 11. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease
474 severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-
475 March 2020: retrospective cohort study. *BMJ*. 2020;369:m1443.
- 476 12. Jekarl DW, Kim JY, Ha JH, Lee S, Yoo J, Kim M, et al. Diagnosis and Prognosis of
477 Sepsis Based on Use of Cytokines, Chemokines, and Growth Factors. *Dis Markers*.
478 2019;2019:1089107.
- 479 13. Pierrakos C, Vincent J-L. Sepsis biomarkers: a review. *Crit Care*. 2010;14:R15.
- 480 14. Pierrakos C, Velissaris D, Bisdorff M, Marshall JC, Vincent J-L. Biomarkers of
481 sepsis: time for a reappraisal. *Crit Care*. 2020;24:287.

- 482 15. Chung K-P, Chang H-T, Lo S-C, Chang L-Y, Lin S-Y, Cheng A, et al. Severe
483 lymphopenia is associated with elevated plasma interleukin-15 levels and increased
484 mortality during severe sepsis. *Shock*. 2015;43:569–75.
- 485 16. Birra D, Benucci M, Landolfi L, Merchionda A, Loi G, Amato P, et al. COVID 19:
486 a clue from innate immunity. *Immunol Res*. 2020;68:161–8.
- 487 17. Moreno-Eutimio MA, López-Macías C, Pastelin-Palacios R. Bioinformatic analysis
488 and identification of single-stranded RNA sequences recognized by TLR7/8 in the
489 SARS-CoV-2, SARS-CoV, and MERS-CoV genomes. *Microbes Infect*. 2020;22:226–9.
- 490 18. Cameron CM, Cameron MJ, Bermejo-Martin JF, Ran L, Xu L, Turner PV, et al.
491 Gene expression analysis of host innate immune responses during Lethal H5N1
492 infection in ferrets. *J Virol*. 2008;82:11308–17.
- 493 19. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte Chemoattractant
494 Protein-1 (MCP-1): An Overview. *J Interferon Cytokine Res*. 2009;29:313–26.
- 495 20. Cameron MJ, Bermejo-Martin JF, Danesh A, Muller MP, Kelvin DJ. Human
496 immunopathogenesis of severe acute respiratory syndrome (SARS). *Virus Res*.
497 2008;133:13–9.
- 498 21. Zhao Y, Qin L, Zhang P, Li K, Liang L, Sun J, et al. Longitudinal COVID-19
499 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild
500 disease. *JCI Insight*. 2020;5.
- 501 22. Rojas JM, Avia M, Martín V, Sevilla N. IL-10: A Multifunctional Cytokine in Viral
502 Infections. *J Immunol Res [Internet]*. 2017 [cited 2020 Jul 16];2017. Available from:
503 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337865/>
- 504 23. Couper KN, Blount DG, Riley EM. IL-10: The Master Regulator of Immunity to
505 Infection. *The Journal of Immunology*. American Association of Immunologists;
506 2008;180:5771–7.
- 507 24. Bermejo-Martin JF, Ortiz de Lejarazu R, Pumarola T, Rello J, Almansa R, Ramírez
508 P, et al. Th1 and Th17 hypercytokinemia as early host response signature in severe
509 pandemic influenza. *Crit Care*. 2009;13:R201.
- 510 25. Perera P-Y, Lichy JH, Waldmann TA, Perera LP. The role of interleukin-15 in
511 inflammation and immune responses to infection: implications for its therapeutic use.
512 *Microbes Infect*. 2012;14:247–61.
- 513 26. Jabri B, Abadie V. IL-15 functions as a danger signal to regulate tissue-resident T
514 cells and tissue destruction. *Nat Rev Immunol*. 2015;15:771–83.
- 515 27. Klingström J, Smed-Sörensen A, Maleki KT, Solà-Riera C, Ahlm C, Björkström
516 NK, et al. Innate and adaptive immune responses against human Puumala virus
517 infection: immunopathogenesis and suggestions for novel treatment strategies for severe
518 hantavirus-associated syndromes. *J Intern Med*. 2019;285:510–23.

- 519 28. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of
520 lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2
521 infected patients. *EBioMedicine*. 2020;55:102763.
- 522 29. Morjaria S, Zhang A, Kaltsas Md A, Parameswaran R, Patel D, Zhou W, et al. The
523 Effect of Neutropenia and Filgrastim (G-CSF) in Cancer Patients With COVID-19
524 Infection. *medRxiv*. 2020;
- 525 30. Lazarus HM, Gale RP. G-CSF and GM-CSF Are Different. Which One Is Better for
526 COVID-19? *AHA*. Karger Publishers; 2020;1–4.
- 527 31. Almansa R, Socias L, Ramirez P, Martin-Loeches I, Vallés J, Loza A, et al.
528 Imbalanced pro- and anti-Th17 responses (IL-17/granulocyte colony-stimulating factor)
529 predict fatal outcome in 2009 pandemic influenza. *Crit Care*. 2011;15:448.
- 530 32. Lachmann G, Knaak C, Vorderwülbecke G, La Rosée P, Balzer F, Schenk T, et al.
531 Hyperferritinemia in Critically Ill Patients. *Crit Care Med*. 2020;48:459–65.
- 532 33. Khinda J, Janjua NZ, Cheng S, van den Heuvel ER, Bhatti P, Darvishian M.
533 Association between markers of immune response at hospital admission and COVID-19
534 disease severity and mortality: A meta-analysis and meta-regression. *J Med Virol*. 2020;
- 535 34. Lu J, Wei Z, Jiang H, Cheng L, Chen Q, Chen M, et al. Lactate dehydrogenase is
536 associated with 28-day mortality in patients with sepsis: a retrospective observational
537 study. *J Surg Res*. 2018;228:314–21.
- 538 35. Rubio I, Osuchowski MF, Shankar-Hari M, Skirecki T, Winkler MS, Lachmann G,
539 et al. Current gaps in sepsis immunology: new opportunities for translational research.
540 *Lancet Infect Dis*. 2019;19:e422–36.
- 541 36. Chung H, Lee JH, Jo YH, Hwang JE, Kim J. Circulating Monocyte Counts and its
542 Impact on Outcomes in Patients With Severe Sepsis Including Septic Shock. *Shock*.
543 2019;51:423–9.
- 544 37. Bermejo-Martin JF, Almansa R, Menendez R, Mendez R, Kelvin DJ, Torres A.
545 Lymphopenic community acquired pneumonia as signature of severe COVID-19.
546 *Journal of Infection*. 2020;
- 547 38. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The
548 SOFA (Sepsis-related Organ Failure Assessment) score to describe organ
549 dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the
550 European Society of Intensive Care Medicine. *Intensive Care Med*. 1996;22:707–10.
- 551
- 552
- 553

	Outpatients (1)	Ward (2)	ICU (3)	<i>p</i> value (1 vs 2)	<i>p</i> value (1 vs 3)	<i>p</i> value (2 vs 3)
554	Conflicts of interests: the authors declare no conflicts of interests regarding this					
555	submission					
556						
557						
558						
559						
560						
561						
562						
563						
564						
565						
566						
567						
568						
569						
570						
571						
572						
573						

Characteristics	Age [years, median (IQR)]	48.50 [19]	64 [20]	66 [19]	<0.001	<0.001	n.s.
	Male [% (n)]	46 (23)	50 (50)	64 (64)	n.s.	0.035	0.046
Comorbidities, [% (n)]	Alcoholism	2 (1)	0 (0)	1 (1)	n.s.	n.s.	n.s.
	Smoking	4 (2)	5 (5)	6 (6)	n.s.	n.s.	n.s.
	Drug abuse	2 (1)	0 (0)	0 (0)	n.s.	n.s.	n.a.
	Cardiac disease	4 (2)	13 (13)	9 (9)	n.s.	n.s.	n.s.
	Chronic vascular disease	2 (1)	2 (2)	5 (5)	n.s.	n.s.	n.s.
		COPD	2 (1)	2 (2)	3 (3)	n.s.	n.s.
	Asthma	8 (4)	6 (6)	2 (2)	n.s.	n.s.	n.s.
	Obesity	4 (2)	26 (26)	26 (26)	0.001	0.001	n.s.
	Hypertension	24 (12)	44 (44)	45 (45)	0.017	0.012	n.s.
	Dyslipidemia	16 (8)	41 (41)	34 (34)	0.002	0.021	n.s.
	Chronic renal disease	2 (1)	3 (3)	3 (3)	n.s.	n.s.	n.s.
	Chronic hepatic disease	2 (1)	0 (0)	3 (3)	n.s.	n.s.	n.s.
	Neurological disease	0 (0)	6 (6)	3 (3)	n.s.	n.s.	n.s.
	HIV	0 (0)	0 (0)	1 (1)	n.a.	n.s.	n.s.
	Autoimmune disease	2 (1)	1 (1)	1 (1)	n.s.	n.s.	n.s.
	Chronic inflammatory bowel disease	0 (0)	2 (2)	1 (1)	n.s.	n.s.	n.s.
	Type 1 diabetes	0 (0)	0 (0)	3 (3)	n.a.	n.s.	n.s.
	Type 2 diabetes	0 (0)	23 (23)	22 (22)	<0.001	<0.001	n.s.
Cancer	6 (3)	2 (2)	1 (1)	n.s.	n.s.	n.s.	
Treatment during hospitalization, [% (n)]	Invasive mechanical ventilation	0 (0)	0 (0)	96 (96)	n.a.	<0.001	<0.001
	Non-invasive mechanical ventilation	0 (0)	15.1 (14)	34 (34)	0.004	<0.001	0.002
	Hydroxychloroquine	77.6 (38)	89 (89)	99 (99)	n.s.	<0.001	0.003
	Chloroquine	4.1 (2)	7 (7)	0 (0)	n.s.	0.042	0.007
	Corticoids	6.7 (3)	29.6 (29)	85 (85)	0.002	<0.001	<0.001
	Azithromycin	15.9 (7)	84.8 (84)	84 (84)	<0.001	<0.001	n.s.
	Remdesivir	0 (0)	1 (1)	9 (9)	n.s.	0.029	0.009
	Tocilizumab	0 (0)	13 (13)	33 (33)	0.008	<0.001	0.001
	Lopinavir/ritonavir	74 (37)	35.4 (35)	96 (96)	<0.001	<0.001	<0.001
Beta Interferon	0 (0)	0 (0)	55.6 (55)	n.a.	<0.001	<0.001	
Time course and outcome	Hospital stay [days, median (IQR)]	-	9 (6)	24 (19)	n.a.	n.a.	<0.001
	Viral RNA in plasma [% (n)]	22 (11)	36 (36)	82 (82)	n.s.	<0.001	<0.001
	SARS-CoV-2 IgG, [% (n)]	52 (26)	49 (49)	70 (70)	n.s.	0.030	0.002
	Hospital mortality, [% (n)]	0 (0)	0 (0)	48 (48)	n.a.	<0.001	<0.001
	Temperature (°C) [median (IQR)]	36.50 (1.0)	36.80 (1.4)	37.00 (1.4)	-	-	-
	Systolic Arterial Pressure (mmHg) [median (IQR)]	120 (29)	126 (25)	120 (26)	n.s.	n.s.	0.013
	Oxygen saturation (%) [median (IQR)]	96 (3)	94 (5)	92 (6)	0.002	<0.001	0.001
	Pulmonary infiltrate [% (n)]	72 (36)	93 (93)	100 (100)	<0.001	<0.001	0.007
	Bilateral pulmonary infiltrate [% (n)]	26 (13)	67 (67)	93 (93)	<0.001	<0.001	<0.001
	Glucose (mg/dl) [median (IQR)]	99.5 (22)	112 (31)	160.50 (83)	0.004	<0.001	<0.001
	Creatinine (mg/dl) [median (IQR)]	0.84 (0.18)	0.91 (0.33)	0.88 (0.57)	-	-	-
	Na (mEq/L) [median (IQR)]	138 (4)	138 (5)	138.50 (7)	-	-	-

Measurements at diagnosis	K (mEq/L) [median (IQR)]	3.90 (0.50)	4.10 (0.68)	3.95 (0.90)	-	-	-
	Platelets (cell x 10³/µl) [median (IQR)]	223 [97]	207 [113]	204 [126]	-	-	-
	INR [median (IQR)]	1.04 (0.10)	1.11 (0.13)	1.22 (0.22)	0.001	< 0.001	< 0.001
	D Dimer (pg/ml) [median (IQR)]	795278 [828234]	1597362.50 [2024704]	6182104.50 [52690922]	< 0.001	< 0.001	< 0.001
	LDH (UI/L) [median (IQR)]	214 (73)	278 (138)	496 (285)	0.002	< 0.001	< 0.001
	GPT (UI/L) [median (IQR)]	27 (43)	29 (29)	44 (44.50)	n.s.	n.s.	0.016
	Ferritin (pg/ml) [median (IQR)]	359507 [458748]	523805 [534757]	923687 [1526492]	n.s.	< 0.001	0.002
	CRP (mg/dl) [median (IQR)]	1.40 (3.50)	40.90 (89.18)	91 (182.10)	< 0.001	< 0.001	0.031
	Haematocrit (%) [median (IQR)]	43.15 (4.72)	42.50 (6.50)	38.15 (6.48)	n.s.	< 0.001	< 0.001
	WBC (cells/mm3) [median (IQR)]	6450 (2815)	7005 (4115)	9145 (6613)	n.s.	< 0.001	0.006
	Lymphocytes (cells/mm3) [median (IQR)]	1400 (805)	1000 (433)	540 (445)	< 0.001	< 0.001	< 0.001
	Neutrophils (cells/mm3) [median (IQR)]	4260 (2625)	5250 (3918)	8300 (5880)	0.046	< 0.001	< 0.001
	Monocytes (cells/mm3) [median (IQR)]	500 (300)	400 (300)	300 (280)	n.s.	< 0.001	0.019
	Eosinophils (cells/mm3) [median (IQR)]	0 (100)	0 (40)	0 (6)	n.s.	n.s.	n.s.
Basophils (cells/mm3) [median (IQR)]	0 (0)	0 (20)	5.25 (17)	0.001	< 0.001	n.s.	

574

575 **Table 1: Clinical characteristics of the patients:** continuous variables are represented

576 as [median, (interquartile range, IQR)]; categorical variables are represented as [%,

577 (n)].; INR, International Normalized Ratio; n.s., not significant; n.a., not applicable.

578 COPD (Chronic obstructive pulmonary disease), HIV (Human Immunodeficiency

579 Virus), INR (International Normalized Ratio), LDH (Lactic Acid Dehydrogenase), GPT

580 (glutamic-pyruvate transaminase); CRP (C-reactive protein), WBC (white blood cell).

581

582

583

584

	GLM (outpatients vs wards)	GLM (wards vs ICU)
--	-----------------------------------	---------------------------

	OR	<i>p</i>	CI 95%		OR	<i>p</i>	CI 95%	
			lower	upper			lower	upper
Viremia	2.12	0.10	0.86	5.20	8.30	< 0.001	4.21	16.34
Age	1.06	< 0.001	1.03	1.09	1.00	0.97	0.98	1.02
Sex	1.06	0.88	0.48	2.32	1.86	0.06	0.97	3.56
Obesity	4.89	0.05	1.02	23.53	1.11	0.78	0.52	2.36
Hypertension	1.19	0.71	0.48	2.95	0.90	0.77	0.44	1.83
Cardiac disease	1.69	0.55	0.29	9.83	0.69	0.51	0.23	2.07
Asthma	1.02	0.98	0.23	4.43	0.26	0.15	0.04	1.62
Dyslipidemia	1.63	0.33	0.60	4.40	0.84	0.66	0.40	1.79

585

586 **Table 2: Multivariate generalized linear model with binomial distribution to assess**
587 **the association between viremia and hospitalization at the wards in the comparison**
588 **(outpatients vs wards) (left) and the association between viremia and**
589 **hospitalization at the ICU in the comparison (wards vs ICU) (right).**

590

591

592

593

594

595

596

597


598 **Figure legends**




599 **Figure 1: Forest plot showing the result from the multivariate generalized linear**
600 **model with a gamma distribution (log-link) to assess the association between**
601 **viremia and laboratory and immunological parameters** Arithmetic mean ratios
602 (AMR) adjusted by major comorbidities (Age, Sex, Obesity, Hypertension, Type II
603 Diabetes, Cardiovascular disease, Asthma, Dyslipidemia) and disease severity category
604 (outpatients, ward and ICU) are showed in the plot.

605 **Figure 2: Box plots showing the immunological mediators' levels across severity**
606 **groups.**


607 **Figure 3: prevalence of SARS-CoV-2-RNA viremia and SARS-CoV-2 IgG**
608 **antibodies in each severity group.**

VIREMIA





SARS-CoV-2 RNA viremia (%)



SARS-CoV-2 IgG (%)

